4//SEC Filing
Valliant John 4
Accession 0001209191-22-025469
CIK 0001805890other
Filed
Apr 21, 8:00 PM ET
Accepted
Apr 22, 8:04 PM ET
Size
7.3 KB
Accession
0001209191-22-025469
Insider Transaction Report
Form 4
Valliant John
DirectorChief Executive Officer
Transactions
- Sale
Common Stock
2022-04-21$6.01/sh−922$5,541→ 326,841 total - Sale
Common Stock
2022-04-20$6.02/sh−367$2,209→ 327,763 total
Footnotes (3)
- [F1]The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2021.
- [F2]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $6.02 to $6.03 per share. The reporting person hereby undertakes, upon request of the staff of the U.S. Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.
- [F3]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $6.00 to $6.05 per share. The reporting person hereby undertakes, upon request of the staff of the U.S. Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.
Documents
Issuer
Fusion Pharmaceuticals Inc.
CIK 0001805890
Entity typeother
Related Parties
1- filerCIK 0001813574
Filing Metadata
- Form type
- 4
- Filed
- Apr 21, 8:00 PM ET
- Accepted
- Apr 22, 8:04 PM ET
- Size
- 7.3 KB